Document:

EX-10.34

 Exhibit 10.34 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 LICENSE
AGREEMENT 
 This Agreement, effective as of November 4, 2013 (the “Effective Date”), is by and between: 

NEW YORK UNIVERSITY (hereinafter “NYU”), a corporation organized and existing under the laws of the State of New York and having a
place of business at 70 Washington Square South, New York, New York 10012 
 AND 

BioNano Genomics, Inc. (hereinafter “CORPORATION”), a corporation organized and existing under the laws of the State of Delaware and
having its principal office at 9640 Towne Centre Drive, Suite 100, San Diego, CA 92121. 
 RECITALS 

WHEREAS, [...***...] of NYU (hereinafter “the NYU Scientist”) together with [...***...], formerly of NYU, have made
certain inventions relating to [...***...], all as more particularly described in a pending U.S. patent application and issued US patents jointly owned by NYU and [...***...] ([...***...]), identified in annexed Appendix I and
forming an integral part hereof (hereinafter “the Pre-Existing Inventions”); 
 WHEREAS,
NYU and [...***...] have entered into an Inter-Institutional Agreement effective [...***...] in which [...***...] grants to NYU the exclusive right on behalf of [...***...] to enter into license Agreements to the Pre-Existing Inventions; 
 WHEREAS, [...***...] have developed software, [...***...], as
described in Appendix II; 
 WHEREAS, subject to the terms and conditions hereinafter set forth, NYU is willing to grant to CORPORATION and
CORPORATION is willing to accept from NYU the License (as hereinafter defined); 
 NOW, THEREFORE, in consideration of the mutual promises
and agreements contained herein, the parties hereto hereby agree as follows: 
  

	1.	Definitions. 

 1.01. “Affiliate” shall mean any company or other legal
entity which controls, or is controlled by, or is under common control with, CORPORATION; control means the holding of greater than fifty percent (50%) of (i) the capital and/or (ii) the voting rights and/or (iii) the right to elect
or appoint directors. 
 1.02. “Calendar Year” shall mean any consecutive period of twelve months commencing on the first day of
January of any year. 

  
 ***Confidential
Treatment Requested 
 1. 

 1.03. “Date of First Commercial Sale” shall mean the date on which a Licensed Product
is first offered for sale by CORPORATION or an Affiliate or sublicensee of CORPORATION. 
 1.04. “Derivative” shall mean any
derivative work, product, device or computer software or code using or based on, in whole or in part, the NYU Software or NYU Copyrights and/or incorporating all or any part of the NYU Software or NYU Copyrights including without limitation,
translations of such a work to other computer _ languages, adaptations of such a work to other hardware platforms or operating systems, and corrections and enhancements of any such work. 

1.05. “Field” shall mean the detection, identification, and analysis of [...***...] organisms with the exception of
microorganisms. 
 1.06. “License” shall mean the non-exclusive, non-sublicensable (except
for end-user licenses) worldwide license to practice the Research Technology (as hereinafter defined) to develop, make, have made, use, offer for sale, sell or have sold the Licensed Products (as hereinafter
defined) in the Field. 
 1.07. “Licensed Products” shall mean all products and services, including without limitation systems,
hardware, and software, covered by a issued claim of any unexpired NYU Patent (as hereinafter defined) which has not been disclaimed or held invalid by a court of competent jurisdiction from which no appeal can be taken, or which incorporates NYU
Software or Research Technology. 
 1.08. “Royalty Bearing Products” shall mean (i) all systems and instruments for the
detection, identification, and analysis of [...***...] organisms; and (ii) consumables, including without limitation chips, cartridges, and reagents; and (iii) all services related to the use of Licensed Products including without
limitation haplotyping services. For the avoidance of doubt, the parties agree that the lrysTM instrument is a Royalty Bearing Product under (i) above if sold without incorporating NYU
Software or Research Technology and is a Licensed Product if sold with NYU Software or incorporating Research Technology. 
 1.09. Net Sales
should mean [...***...] to any person or entity that is not an Affiliate of CORPORATION under the License, after deduction of all the following to the extent applicable to such sales; 

	 	i)	[...***...] 

	 	ii)	[...***...] 

	 	iii)	[...***...]; 

	 	iv)	[...***...]; 

	 	v)	[...***...] 

	 	vi)	[...***...] 

  
 ***Confidential
Treatment Requested 
 2. 

 Net Sales shall be [...***...] 

1.10. “NYU Copyrights” shall mean NYU’s interest in all United States and foreign copyrights in the NYU Software (as
hereinafter defined), including but not limited to software, animation, characters, algorithms, screen design, text, storyboard, scenario, video, and medical imaging masks, and any Derivative thereof developed by CORPORATION or its Affiliates. 

1.11. “NYU Patents” shall mean all United States and foreign patents and patent applications, and any existing and future
divisionals, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor which claim Pre-Existing Inventions and which are identified on annexed Appendix I.

 1.12. “NYU Software” shall mean NYU’s interest in the [...***...] software and computer code, or any portion thereof
and which are identified on annexed Appendix II. 
 1.13. “Research Technology” shall mean all NYU Patents and NYU Copyrights.

  

	2.	Effective Date. 

 This Agreement shall be effective as of the Effective Date and
shall remain in full force and effect until it expires or is terminated in accordance with Section 13 hereof. 
  

	3.	Title. 

 3.01. It is hereby agreed that all right, title and interest, in and to
the Research Technology, and in and to any drawings, plans, diagrams, specifications, and other documents containing any of the Research Technology shall vest solely in NYU. At the request of NYU, CORPORATION shall take all steps as may be necessary
to give full effect to said right, title and interest of NYU including, but not limited to, the execution of any documents that may be required to record such right, title and interest with the appropriate agency or government office. 

3.02. For so long as the NYU Scientist is employed by NYU, any and all inventions made by the NYU Scientist and relating to the Field shall be
owned solely by NYU. 
  

	4.	Patents and Patent Applications. 

 4.01. At the initiative of CORPORATION or NYU,
the parties shall consult with each other regarding the prosecution of all patent applications with respect to the Research Technology. Such patent applications shall be filed, prosecuted and maintained by the law firm of Dorsey & Whitney
or by other patent counsel jointly selected by NYU and CORPORATION. Copies of all such patent applications and patent office actions shall be forwarded in a timely manner to each of NYU and CORPORATION. NYU and CORPORATION shall each also have the
right to have such patent applications and patent office actions independently reviewed by other 

  
 ***Confidential
Treatment Requested 
 3. 

 patent counsel separately retained by NYU or CORPORATION, upon prior notice to and consent of the other party,
which consent shall not unreasonably be withheld. 
 4.03. All applications and proceedings with respect to the NYU Patents shall be filed,
prosecuted and maintained by NYU in NYU’s sole discretion. NYU shall be free to abandon any NYU Patent. 
 4.04 NYU agrees to provide
written notification to the CORPORATION if NYU intends to terminate prosecution of any patent applications identified in Appendix I or filed with respect to the Research Technology. 

4.05 Nothing herein contained shall be deemed to be a warranty by NYU that 

 

	 	i)	NYU can or will be able to obtain any patent or patents on any patent application or applications in the NYU Patents or any portion thereof, or that any of the NYU Patents will afford adequate or commercially worthwhile
protection, or 

  

	 	ii)	that the manufacture, use, or sale of any element of the Research Technology or any Licensed Product will not infringe any patent(s) of a third party. 

4.06. CORPORATION and any Affiliates of CORPORATION shall insure that they apply patent markings that meet all requirements of U.S. law, 35
U.S.C. § 287, with respect to all Licensed Products. 
  

	5.	Grant of License. 

 5.01. Subject to the terms and conditions hereinafter set
forth, NYU hereby grants to CORPORATION and CORPORATION hereby accepts from NYU the License. 
 5.02. NYU reserves the right to use, and to
permit other non-commercial entities to use, the Research Technology for educational and research purposes, 

5.03. The parties acknowledge that the United States government retains rights in intellectual property funded under any grant or similar
contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual property and are sold in
the United States, must be substantially manufactured in the United States. 
 5.04. The License granted to CORPORATION in Section 5.01
hereto shall commence upon the Effective Date and shall remain in force on a country-by-country basis, if not previously terminated under the terms of this Agreement,
for fifteen (15) years from the Date of First Commercial Sale in such country or until the expiration date of the last to expire of the NYU Patents whichever shall be later. CORPORATION shall inform NYU in writing of the Date of First
Commercial Sale with respect to each Licensed Product in each country as soon as practicable after the making of each such first commercial sale. 

  
 4. 

 5.05. The CORPORATION will retain ownership of any improvements or developments of the Research
Technology made solely by the CORPORATION, other than Derivatives. 
  

	6.	Payments for License. 

 6.01. In consideration for the grant and during the term
of the License with respect to each Licensed Product, CORPORATION shall pay to NYU: 
  

	 	(a)	on the Effective Date, a non-refundable, non-creditable license issue fee of [...***...]; and 

 

	 	(b)	a royalty on the Net Sales of CORPORATION and each Affiliate of CORPORATION as follows: 

  

	 	(i)	[...***...] of the Net Sales of consumables consisting of [...***...]; and 

  

	 	(ii)	[...***...] of the Net Sales of services including without [...***...]; and 

  

	 	(iii)	[...***...] of all other Net Sales. 

  

	 	(c)	a milestone payment of [...***...] upon the [...***...], including without limitation [...***...]. 

6.02. Beginning with Calendar Year 2014 and continuing thereafter until this Agreement shall terminate or expire, CORPORATION agrees that if
the total royalties paid to NYU under subsection 6.01(b) hereof do not amount to [...***...] in each Calendar Year, CORPORATION will pay to NYU within [...***...] after the end of each such Calendar Year, as additional royalty, the
difference between the [...***...], failing which NYU shall have the right solely at Its election, upon written notice to CORPORATION, to terminate this Agreement for cause. 

6.03. For the purpose of computing the royalties due to NYU hereunder, the year shall be divided into four parts ending on March 31,
June 30, September 30, and December 31. Not later than [...***...] after each December, March, June, and September in each Calendar Year during the term of the License, CORPORATION shall submit to NYU a full and detailed report of
royalties or payments due NYU under the terms of this Agreement for the preceding quarter year (hereinafter “the Quarter-Year Report”), setting forth the Net Sales and/or lump sum payments and all other payments or consideration upon which
such royalties are computed and including at least 
  

	 	i)	the quantity of Licensed Products and Royalty Bearing Products used, sold, transferred or otherwise disposed of; 

  
 ***Confidential
Treatment Requested 
 5. 

	 	ii)	the selling price of each Licensed Product; 

  

	 	iii)	the deductions permitted under subsection 1.09 hereof to arrive at Net Sales; and 

  

	 	iv)	the royalty computations and subject of payment. 

 If no royalties or other payments are due, a
statement shall be sent to NYU stating such fact. Payment of the full amount of any royalties or other payments due to NYU for the preceding quarter year shall accompany each Quarter-Year Report on royalties and payments. CORPORATION shall keep for
a period of at least six (6) years after the date of entry, full, accurate and complete books and records consistent with sound business and accounting practices and in such form and in such detail as to enable the determination of the amounts
due to NYU from CORPORATION pursuant to the terms of this Agreement. 
 6.04. On reasonable notice and during regular business hours, NYU or
the authorized representative of NYU shall each have the right to inspect the books of accounts, records and other relevant documentation of CORPORATION or of Affiliates of CORPORATION insofar as they relate to the production, marketing and sale of
the Licensed Products and Royalty Bearing Products, in order to ascertain or verify the amount of royalties and other payments due to NYU hereunder, and the accuracy of the information provided to NYU in the aforementioned reports. The cost of such
inspection shall be borne by NYU, unless it is determined in such inspection that NYU has been underpaid in any period by more than [...***...] of the amount which NYU should have been paid, in which case the cost of such inspection shall be
reimbursed to NYU by CORPORATION. 
  

	7.	Method of Payment. 

 7.01. Royalties and other payments due to NYU hereunder shall
be paid to NYU in United States dollars. Any such royalties on or other payments relating to transactions in a foreign currency shall be converted into United States dollars based on the closing buying rate of the Morgan Guaranty Trust Company of
New York applicable to transactions under exchange regulations for the particular currency on the last business day of the accounting period for which such royalty or other payment is due. 

7.02. CORPORATION shall be responsible for payment to NYU of all royalties due on sale, transfer or disposition of Licensed Products and
Royalty Bearing Products by each Affiliate of CORPORATION. 
 7.03. Any amount payable hereunder by one of the parties to the other, which
has not been paid by the date on which such payment is due, shall bear interest form such date until the date on which such payment is made, at the rate of [...***...] per annum in excess of the prime rate prevailing at the Citibank, N.A., in
New York, during the period of arrears and such amount and the interest thereon may be set off against any amount due, whether in terms of this Agreement or otherwise, to the party in default by any
non-defaulting party. 
  

  
 ***Confidential
Treatment Requested 
 6. 

	8.	Development and Commercialization. 

 8.01. CORPORATION undertakes to use
continuous reasonable diligence to make and sell Licensed Products, including but not limited to, the performance of all efficacy, pharmaceutical, safety, toxicological and clinical tests, trials and studies and all other activities necessary in
order to obtain the approval of the FDA for the production, use and sale of the Licensed Products, all as set forth in the Development Plan (annexed hereto as Appendix III and which is an integral part of this Agreement) and within all timetables
set forth therein. CORPORATION further undertakes to exercise due diligence and to employ its reasonable diligence to obtain, the appropriate approvals of the health authorities for the production, use and sale of the Licensed Products, in each of
the other countries of the world in which CORPORATION intend to produce, use, and/or sell Licensed Products. 
 8.02. Provided that
applicable laws, rules and regulations require that the performance of the tests, trials, studies and other activities specified in Paragraph 8.01 above shall be carried out in accordance with FDA Good Laboratory Practices and in a manner acceptable
to the relevant health authorities, CORPORATION shall carry out such tests, trials, studies and other activities in accordance with FDA Good Laboratory Practices and in a manner acceptable to the relevant health authorities. Furthermore, the
Licensed Products shall be produced in accordance with FDA Good Manufacturing Practice (“GMP”) procedures in a facility which has been certified by the FDA as complying with GMP, provided that applicable laws, rules and regulations so
require. 
 8.03. CORPORATION undertakes to begin the regular commercial production, use, and sale of the Licensed Products in good faith in
accordance with the Development Plan and to continue diligently thereafter to commercialize the Licensed Products. 
 8.04. CORPORATION
shall provide NYU with written annual reports on all activities and actions undertaken by CORPORATION to develop and commercialize the Licensed Products; such reports shall be made within sixty (60) days after each June 30th for the duration of
this Agreement. 
 8.05. If CORPORATION shall not commercialize the Licensed Products within a reasonable time frame, unless such delay is
necessitated by FDA or other regulatory agencies or unless NYU and CORPORATION have mutually agreed to amend the Development Plan because of unforeseen circumstances, NYU shall notify CORPORATION in writing of CORPORATION’s failure to
commercialize and shall allow CORPORATION sixty (60) days to cure its failure to commercialize. CORPORATION’s failure to cure such delay to NYU’s reasonable satisfaction within such 60-day
period shall be a material breach of this Agreement. 
  

	9.	CONFIDENTIAL INFORMATION. 

  
 7. 

 9.01. Except as otherwise provided in Section 9.02 and 9.03 below CORPORATION shall maintain
any and all of the Research Technology in confidence and shall not release or disclose any tangible or intangible component thereof to any third party without first receiving the prior written consent of NYU to said release or disclosure. 

9.02. The obligations of confidentiality set forth in Sections 9.01 shall not apply to any component of the Research Technology which was part
of the public domain prior to the Effective Date of this Agreement or which becomes a part of the public domain not due to some unauthorized act by or omission of CORPORATION after the effective date of this Agreement or which is disclosed to the
CORPORATION by a third party who has the right to make such disclosure. 
 9.03. The provisions of Section 9.01 notwithstanding,
CORPORATION may disclose the Research Technology to third parties who need to know the same in order to secure regulatory approval for the sale of Licensed Products. 
  

	10.	Infringement of NYU Patent. 

 10.01. In the event a party to this Agreement
acquires information that a third party is infringing one or more of the NYU Patents, the party acquiring such information shall promptly notify the other party to the Agreement in writing of such infringement. 

10.02. As between the parties, NYU shall have the sole right but not the obligation to pursue any infringers and to retain any recovery
therefrom. NYU may grants such rights to third parties. 
  

	11.	Liability and Indemnification. 

 11.01. CORPORATION shall indemnify, defend and
hold harmless NYU and its trustees, officers, medical and professional staff, employees, students and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss or expense (including
reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments (i) arising out of the design, production,
manufacture, sale, use in commerce or in human clinical trials, lease, or promotion by CORPORATION or by a licensee, Affiliate or agent of CORPORATION of any Licensed Product or Royalty Bearing Product, process or service relating to, or developed
pursuant to, this Agreement or (ii) arising out of any other activities to be carried out pursuant to this Agreement. 
 11.02. With
respect to an Indemnitee, CORPORATION’s indemnification under subsection 11.01(i) shall apply to any liability, damage, loss or expense whether or not it is attributable to the negligent activities of such Indemnitee. CORPORATION’s
indemnification obligation under subsection 11.01(ii) shall not apply to any liability, damage, loss or expense to the extent that it is attributable to the negligent activities of any such Indemnitee. 

  
 8. 

 11.03. CORPORATION agrees, at its own expense, to provide attorneys reasonably acceptable to NYU
to defend against any actions brought or filed against any Indemnitee with respect to the subject of indemnity to which such Indemnitee is entitled hereunder, whether or not such actions are rightfully brought. 

 

	12.	Security for Indemnification. 

 12.01. At such time as any Licensed Product or
Royalty Bearing Product, process or service relating to, or developed pursuant to, this Agreement Is being commercially distributed or sold or tested in clinical trials by CORPORATION or by a licensee, Affiliate or agent of CORPORATION, CORPORATION
shall at its sole cost and expense, procure and maintain policies of comprehensive general liability insurance in amounts not less than $[...***...] per incident and $[...***...] annual aggregate during the period that such Licensed
Product, Royalty Bearing Product, process, or service is being tested in clinical trials or commercially distributed or sold, and in each case naming the Indemnitees as additional insureds. Such comprehensive general liability insurance, shall
provide (i) product liability coverage and (ii) broad form contractual liability coverage for CORPORATION’s indemnification under Section 11 of this Agreement. If CORPORATION elects to self-insure all or part of the limits
described above (including deductibles or retentions which are in excess of $[...***...] annual aggregate) such self-insurance program shall include assets or reserves which have been actuarially determined for the liabilities associated with
this Agreement and must be acceptable to NYU. 
 The minimum amounts of insurance coverage required under this Section 12 shall not be
construed to create a limit of CORPORATION’s liability with respect to its indemnification under Section 11 of this Agreement. 

12.02. CORPORATION shall provide NYU with written evidence of such insurance upon request of NYU. CORPORATION shall provide NYU with written
notice at least sixty (60) days prior to the cancellation, non-renewal or material change in such insurance; if CORPORATION does not obtain replacement insurance providing comparable coverage within such
sixty (60) day period, NYU shall have the right to terminate this Agreement effective at the end of such sixty (60) day period without notice or any additional waiting periods. 

12.03. CORPORATION shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement during
(i) the period that any product, process or service, relating to, or developed pursuant to, this Agreement is being commercially distributed or sold or tested in clinical trials by CORPORATION or by an Affiliate or agent of CORPORATION and,(ii)
a reasonable period after the period referred to in (i) above which in no event shall be less than five (5) years. 
  

	13.	Expiry and Termination 

 13.01. Unless earlier terminated pursuant to this
Section 13 or Section 6.02, hereof, this Agreement shall expire upon the expiration of the period of the License in all countries as set forth in Section 5.04 above. 

***Confidential Treatment Requested 

  
 9. 

 13.02. At any time prior to expiration of this Agreement, either party may terminate this
Agreement forthwith for cause, as “cause” is described below, by giving written notice to the other party. Cause for termination by one party of this Agreement shall be deemed to exist if the other party materially breaches or defaults In
the performance or observance of any of the provisions of this Agreement and such breach or default is not cured within sixty (60) days or, in the case of failure to pay any amounts due hereunder, thirty (30) days (unless otherwise
specified herein) after the giving of notice by the other party specifying such breach or default, or if either NYU or CORPORATION discontinues its business or becomes insolvent or bankrupt. 

13.03. Upon termination of this Agreement for any reason and prior to expiration as set forth in Section 13.01 hereof, all rights in and
to the Research Technology shall revert to NYU, and CORPORATION shall not be entitled to make any further use whatsoever of the Research Technology. 

13.04. CORPORATION may terminate this Agreement by giving ninety (90) days’ advance written notice of termination to NYU. 

13.05. This Agreement may be terminated by mutual written consent of both parties. 

13.06. Termination of this Agreement shall not relieve either party of any obligation to the other party incurred prior to such termination.

 13.07. Sections 3, 9, 11, 12, 13 and 17 hereof shall survive and remain in full force and effect after any termination, cancellation or
expiration of this Agreement. 
 14. Representations and Warranties by CORPORATION. 

CORPORATION hereby represents and warrants to NYU as follow: 

(1) CORPORATION is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. CORPORATION has
been granted all requisite power and authority to carry on its business and to own and operate its properties and assets. The execution, delivery and performance of this Agreement has been duly authorized by CORPORATION 

(2) There is no pending or, to CORPORATION’s knowledge, threatened litigation involving CORPORATION which would have any effect on this
Agreement or on CORPORATION’s ability to perform its obligations hereunder; and 
 (3) There is no indenture, contract, or agreement to
which CORPORATION is a party or by which CORPORATION is bound which prohibits or would prohibit the execution and delivery by CORPORATION of this Agreement or the performance or observance by CORPORATION of any term or condition of this Agreement,

  

	15.	Representations and Warranties by NYU. 

 NYU hereby represents and warrants to
CORPORATION as follows: 
 (1) NYU is a corporation duly organized, validly existing and in good standing under the laws of the State of New
York. NYU has been granted all requisite power and authority to carry on its business and to own and operate its properties and 

  
 10. 

 assets. The execution, delivery and performance of this Agreement have been duly authorized by the Board of
Trustees of NYU. 
 (2) There is no pending or, to NYU’s knowledge, threatened litigation involving NYU which would have any effect on
this Agreement or on NYU’s ability to perform its obligations hereunder; and 
 (3) There is no indenture, contract, or agreement to
which NYU is a party or by which NYU is bound which prohibits or would prohibit the execution and delivery by NYU of this Agreement or the performance or observance by NYU of any term or condition of this Agreement. 

 

	16.	No Assignment. 

 Neither CORPORATION nor NYU shall have the right to assign,
delegate or transfer at any time to any party, in whole or In part, any or all of the rights, duties and interest herein granted without first obtaining the written consent of the other to such assignment. 

 

	17.	Use of Name. 

 Without the prior written consent of the other party, neither
CORPORATION nor NYU shall use the name of the other party or any adaptation thereof or of any staff member, employee or student of the other party: 
  

	 	i)	in any product labeling, advertising, promotional or sales literature; 

  

	 	ii)	in connection with any public or private offering or in conjunction with any application for regulatory approval, unless disclosure is otherwise required by law, in which case either party may make factual statements
concerning the Agreement or file copies of the Agreement after providing the other party with an opportunity to comment and reasonable time within which to do so on such statement in draft. 

Except as provided herein, neither NYU nor CORPORATION will issue public announcements about this Agreement without prior written approval of
the other party. 
  

	18.	Miscellaneous, 

 18.01. In carrying out this Agreement the parties shall comply
with all local, state and federal laws and regulations including but not limited to, the provisions of Title 35 United States Code §200 et seq. and 15 CFR §368 et seq. 

18.02. If any provision of this Agreement is determined to be invalid or void, the remaining provisions shall remain in effect. 

18.03. This Agreement shall be governed by and construed in accordance with the laws of New York, without regard to principles relating to
conflicts of law. The courts of the State of New York in New York County and the United States District Court for the Southern District of New York shall have exclusive jurisdiction over the parties with respect to any dispute or controversy between
them arising under or in connection with this Agreement and, by execution and delivery of this Agreement, the parties to this Agreement submit to the jurisdiction of those courts, including, but not limited to, the in personam and subject matter
jurisdiction of those courts, waive any objection to such jurisdiction on the grounds of venue or forum non conveniens, the 

  
 11. 

 
absence of in personam or subject matter jurisdiction and any similar grounds, consent to service of process by mail in accordance with paragraph 18.04 or any other manner permitted by law and
irrevocably agree to be bound by any such judgment rendered thereby in connection with this Agreement. These consents to jurisdiction shall not be deemed to confer rights on any person other than the parties to this Agreement. 

18.04. All payments or notices required or permitted to be given under this Agreement shall be given in writing and shall be effective when
either personally delivered or deposited, postage prepaid, in the United States registered or certified mail, or with a recognized overnight delivery service (e.g., Federal Express or DHL), addressed as follows: 

To NYU:    New York University 

Office of Industrial Liaison 

One Park Avenue, 6th Floor 

New York, NY 10016 
 Attention:
Abram M. Goldfinger 
 Executive Director, 

Industrial Liaison/Technology Transfer 

and 
 Office of Legal Counsel

 New York University 
 Bobst
Library 
 70 Washington Square South 

New York, NY 10012 
 Attention:
Mark Righter, Esq 
 Associate General Counsel 

To CORPORATION: 
 BioNano
Genomics, Inc. 
 9640 Towne Centre Drive, Suite 100 

San Diego, CA 92121 
 Attention:
Erik Holmlin 
 President and CEO 

or such other address or addresses as either party may hereafter specify by written notice to the other. Such notices and communications shall
be deemed effective on the date of delivery or fourteen (14) days after having been sent by registered or certified mail, whichever is earlier. 

18.05. This Agreement (and the annexed Appendix) constitute the entire Agreement between the parties and no variation, modification or waiver
of any of the 

  
 12. 

 terms or conditions hereof shall be deemed valid unless made in writing and signed by both parties hereto, This
Agreement supersedes any and all prior agreements or understandings, whether oral or written, between CORPORATION and NYU. 
 18.06. No
waiver by either party of any non-performance or violation by the other party of any of the covenants, obligations or agreements of such other party hereunder shall be deemed to be a waiver of any subsequent
violation or non-performance of the same or any other covenant, agreement or obligation, nor shall forbearance by any party be deemed to be a waiver by such party of its rights or remedies with respect to such
violation or non-performance. 
 18.07. The descriptive headings contained in this Agreement are
included for convenience and reference only and shall not be held to expand, modify or aid in the interpretation, construction or meaning of this Agreement. 

18.08. It is not the intent of the parties to create a partnership or joint venture or to assume partnership responsibility or liability. The
obligations of the parties shall be limited to those set out herein and such obligations shall be several and not joint. 
 IN WITNESS
WHEREOF, the parties hereto have executed this Agreement effective as of the date and year first above written. 
  

			
	NEW YORK UNIVERSITY
		
	By:	 	/s/ Abram M. Goldfinger
		 	Abram M. Goldfinger
		 	Executive Director,
		 	Industrial Liaison/Technology Transfer
		
	Date:	 	11/20/13

  

			
	CORPORATION
		
	By:	 	/s/ Erik Holmlin
		 	Erik Holmlin
	Title:	 	President and CEO
		
	Date:	 	19-NOV-2013

  
 13. 

 Appendix I 

[...***...] 
 [...***...] 

  
 ***Confidential
Treatment Requested 
 14. 

 Appendix II 

[...***...] 
 [...***...] 

  
 ***Confidential
Treatment Requested 
 15. 

 Appendix III 

[...***...] 
 [...***...] 

  
 ***Confidential
Treatment Requested 
 16.EX-10.35

 Exhibit 10.35 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 OPTION AND
SUBLICENSE AGREEMENT 
 THIS OPTION AND SUBLICENSE AGREEMENT (“Agreement”) dated as of
February 2, 2016 (“Effective Date”), is entered into among Pacific Biosciences of California, Inc., a Delaware corporation having an address of 1380 Willow Rd., Menlo Park, CA 94025 (“PacBio”) and BioNano
Genomics, Inc., a Delaware corporation with its principal place of business located at 9640 Towne Centre Drive, Ste. 100, San Diego, CA 92121 (“BioNano”). 

W I T N E S S E T H 

WHEREAS, PacBio controls certain patents related to analysis of nucleic acid molecules in nanofluidic channels; and 

WHEREAS, BioNano desires to obtain a nonexclusive sublicense to such patents controlled by PacBio in order to develop,
manufacture, have manufactured and commercially exploit products in the Territory in the Mapping Field as well as an option to obtain a royalty-bearing sublicense to such patents in the Territory in the Sequencing Field, and PacBio desires to grant
such sublicense and option to BioNano, upon the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE I DEFINITIONS 

For purposes of this Agreement, the following terms when used with initial capital letters shall have the respective meanings
set forth below. 
 1.1 “Acquisition” shall mean a transaction with a Third Party comprising a merger or
reverse merger coupled with a change of control, a sale of substantially all assets relating to this Agreement, a stock purchase agreement or exchange of stock with a third party (other than an equity investment in original issue stock the primary
purpose of which is financing BioNano, where the investor is not a company whose primary business includes nucleic acid sequencing or any affiliate of such company) resulting in a change in control of BioNano. 

1.2 “Affiliate” of a Party shall mean any person, corporation, joint venture or other business entity which,
directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Party, as the case may be. As used in this Section 1.2, “control” shall mean: (a) to possess,
directly or indirectly, the power to affirmatively direct the management and policies of such person, corporation, joint venture or other business entity, whether through ownership of voting securities or by contract relating to voting rights or
corporate governance; or (b) direct or indirect beneficial ownership of fifty percent (50%) or 

  
 ***Confidential
Treatment Requested 
 -1- 

 more of the voting share capital in such person, corporation, joint venture or other business
entity. 
 1.3 “Mapping Field” shall mean detection in a NDS of sequence-related features of a
polynucleotide molecule, [...***...]. 
 1.4 “NDS” shall mean a nano-dimensioned structure having a
hole or channel with at least one dimension that is between [...***...]. For clarity, [...***...]. 
 1.5
“Party” shall mean PacBio or BioNano (together, the “Parties”). 
 1.6 “Sequencing
Field” shall mean detecting and sequentially identifying each nucleotide of the sequence of a polynucleotide molecule in a NDS [...***...]. 

1.7 “Sublicensed Patents” shall mean the patents set forth on Exhibit 1.7. 

1.8 “Territory” shall mean the entire world. 

1.9 “Third Party” shall mean any person, corporation, joint venture or other business entity, other than
BioNano, PacBio and their respective Affiliates. 
 1.10 Additional Definitions. Each of the following definitions
shall have the meanings defined in the corresponding sections of this Agreement indicated below. 
  

			
	 Defined Term
	  	Section
	 Agreement
	  	Preamble
	 BioNano
	  	Preamble
	 [ *** ]
	  	3.3
	 Disclosing Party
	  	6.1
	 Effective Date
	  	Preamble
	 [...***...]
	  	3.3
	 Infringement
	  	7.2

  
 ***Confidential
Treatment Requested 
 -2- 

			
	 Losses
	  	10.1
	 Mapping Products
	  	2.1
	 Net Sales
	  	Exhibit 2.4 (A)
	 PacBio
	  	Preamble
	 Proprietary Information
	  	6.1
	 Recipient
	  	6.1
	 Sequencing Field Option
	  	2.4
	 Sequencing Products
	  	2.4

 ARTICLE II 

GRANT OF SUBLICENSE; OPTION 

2.1 Sublicense. Subject to the terms and conditions of this Agreement, PacBio hereby grants to BioNano a fully paid-up irrevocable nonexclusive sublicense under the Sublicensed Patents only, to import, make, have made, use, offer for sale and sell products and services, solely in the Mapping Field (“Mapping
Products”), and to allow its ultimate customers to use Mapping Products made and sold under the sublicense for their intended purpose solely in the Mapping Field. 

2.2 Extension of Sublicense to Affiliates. BioNano may extend its rights under the sublicense granted in
Section 2.1, and if the Sequencing Field Option is exercised, the sublicense granted under Section 2.4, to one or more of its Affiliates who agree (or for whom BioNano agrees) to assume the same obligations of BioNano under this Agreement;
provided that BioNano shall remain responsible to PacBio for such Affiliate’s compliance with the obligations under this Agreement which apply to such Affiliate. 

2.3 No Further Sublicensing. BioNano may not grant sublicenses to Third Parties under the sublicense granted in
Section 2.1 or, if granted, the sublicense granted in Section 2.4. 
 2.4 Sequencing Field Option. Subject
to the terms and conditions of this Agreement, PacBio hereby grants to BioNano a nonexclusive option (the “Sequencing Field Option”) to obtain a nonexclusive sublicense under the Sublicensed Patents only, to import, make, have made,
use, offer for sale and sell products and services, solely in the Sequencing Field 

  
 -3- 

 (“Sequencing Products”), and to allow its ultimate customers to use Sequencing
Products made and sold under the sublicense for their intended purpose solely in the Sequencing Field.BioNano may exercise the Sequencing Field Option at any time during the Term by providing written notice to PacBio and payment of the option
exercise fee set forth in Section 4.2. Upon such exercise and payment of the option exercise fee, PacBio will automatically grant to BioNano a royalty-bearing, nonexclusive sublicense under the Sublicensed Patents, to import, make, have made,
use, offer for sale and sell products and services, solely in the Sequencing Field, and to allow its ultimate customers to use products made and sold under the sublicense for their intended purpose solely in the Sequencing Field. The financial terms
and conditions of such royalty bearing sublicense are set forth on Exhibit 2.4 to this Agreement. 
 2.5 No Other
Rights. Except as expressly granted herein, neither Party, by implication, estoppel, reliance or otherwise, grants any license or other right under its intellectual property to the other Party. No license or other right to any patents, except
those included in the Sublicensed Patents, are conveyed by PacBio. 
 ARTICLE III 

DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS 

3.1 General Responsibilities. BioNano will be responsible for the development and commercialization of Mapping Products
and Sequencing Products as it deems appropriate in its sole discretion. 
 3.2 Marking Products; [...***...]
License. 
 (a) Patent Marking. BioNano shall mark Mapping Products and, after the exercise of the Sequencing
Field Option, Sequencing Products (or their containers or labels) made, sold, leased, imported, exported or otherwise disposed of by it or its Affiliates under the sublicense(s) granted in this Agreement with the numbers of the applicable
Sublicensed Patent(s); provided that such patent notice shall be in accordance with the laws concerning the marking of patented articles in the country in which such articles are sold. 

(b) [...***...] License. Beginning immediately after the Effective Date for Mapping Products and after the
exercise of the Sequencing Field Option for Sequencing Products, BioNano shall [...***...] that it sells or offers for sale or otherwise commercializes, with [...***...], and shall include [...***...] shall (A) be in
the form attached hereto as Exhibit 3.2 or (B) such other form approved by PacBio that [...***...] and is limited to the Mapping Field or Sequencing Field, as applicable. If applicable law or regulation requires in order for the
restrictions of such [...***...] to be enforceable that any such form(s) be modified, the Parties  

  
 ***Confidential
Treatment Requested 
 -4- 

 agree to so modify such form(s). For the avoidance of doubt, inclusion of such [...***...]
in the manual associated with a Mapping Product or Sequencing Product shall be considered [...***...] such Product for purpose of the preceding sentence. In connection with clause (B), BioNano shall provide to PacBio, for its review and
approval, any such other form of [...***...] and PacBio shall respond (with its approval or with requested changes) within [...***...] thereafter, or shall be deemed to have approved such language for purposes of this Section 3.2.

 3.3 Use of [...***...] Names. BioNano shall not use, nor shall BioNano permit any of its Affiliates
to use, the names, trademarks and indicia of [...***...] (“[...***...]”) or of [...***...] (“[...***...]”), nor the names of any employee, student or faculty member of [...***...] nor
of [...***...], in connection with the activities contemplated under this Agreement, without prior written approval from [...***...]. 

ARTICLE IV 
 UPFRONT AND
OPTION PAYMENTS 
 4.1 Upfront Payment. Subject to the terms and conditions of this Agreement, in further
consideration of the option and sublicense granted by PacBio to BioNano under this Agreement, BioNano shall pay to PacBio an upfront one-time payment of [...***...], payable in [...***...], with
[...***...] due and payable within [...***...] after [...***...] occurring after the Effective Date in which BioNano, its Affiliate(s) and/or its or their shareholders [...***...], but no later than [...***...] after
the Effective Date. The [...***...] shall be due and payable no later than [...***...]. 
 4.2 Option
Exercise Fee. Subject to the terms and conditions of this Agreement, if BioNano exercises the Sequencing Field Option, BioNano shall pay to PacBio a one-time payment of [...***...] payable within
[...***...] after providing written notice to PacBio of the exercise of the Sequencing Field Option. 
 ARTICLE V 

PAYMENT TERMS 

  
 ***Confidential
Treatment Requested 
 -5- 

 5.1 Payment Method. Unless otherwise expressly stated in this Agreement,
all amounts specified in this Agreement shall be in United States dollars. 
 5.2 Withholding Taxes. All payments by
BioNano to PacBio hereunder (including any royalty payments on Sequencing Products) shall be made free and clear of and without reduction for any taxes, duties or similar charges imposed by any government (other than taxes on the net income of
PacBio), which shall be paid by BioNano. Accordingly, if BioNano is required to withhold any taxes on the amounts payable to PacBio hereunder, BioNano shall pay PacBio such additional amounts as are necessary to ensure receipt by PacBio of the full
amount which PacBio would have received but for the deduction on account of such withholding. BioNano shall provide PacBio with official receipts issued by the appropriate governmental agency or such other evidence as is reasonably requested by
PacBio to establish that such taxes have been paid. Each party shall provide the other party with such assistance as shall reasonably be requested in connection with any application to qualify for the benefit of a reduced rate of withholding
taxation, under the terms of any income tax treaty between the United States of America and other jurisdictions. 
 ARTICLE VI 

CONFIDENTIALITY 

6.1 Proprietary Information. Except as otherwise provided in this Article 6, during the term of this Agreement and for
a period of [...***...] thereafter, each Party (the “Recipient”) shall maintain in confidence and use only for purposes of this Agreement any confidential information, data and materials supplied to such Party by the other
Party (the “Disclosing Party”) under this Agreement; provided that, unless the confidentiality of any information, data or material is expressly provided in this Agreement, if any such information, data or materials are in tangible
form, they are marked “Confidential” or “Proprietary,” or if disclosed orally, they are identified as confidential or proprietary when disclosed and are confirmed in writing as confidential or proprietary within [...***...]
following such disclosure (such information, data and materials so disclosed, collectively “Proprietary Information”). The obligations of the Recipient under this Article 6 not to disclose or use Proprietary Information received
from the Disclosing Party shall not apply, however, apply to the extent that any such information, data or materials: 
 (a)
are or become generally available to the public, or otherwise part of the public domain, other than by acts or omissions of the Recipient in breach of this Agreement; 

(b) are disclosed to the Recipient, other than under an obligation of confidentiality, by a Third Party who had no obligation
to the Disclosing Party not to disclose such information to others; 
 (c) were already in the possession of the Recipient,
other than under an obligation of confidentiality, prior to disclosure by the Disclosing Party; or 

  
 ***Confidential
Treatment Requested 
 -6- 

 (d) is subsequently and independently developed by the Recipient without use of
or reference to the Proprietary Information of the Disclosing Party. 
 6.2 Permitted Disclosures. To the extent it
is reasonably necessary or appropriate to fulfill its obligations or exercise its rights under this Agreement: 
 (a) a
Recipient may disclose Proprietary Information which it is otherwise obligated under this Article 6 not to disclose, to its Affiliates, employees, consultants, and outside contractors, on a need-to-know basis in accordance with the exercise of rights granted to such Recipient under this Agreement; provided that such persons agree to be bound by obligations of confidentiality with respect to such
Proprietary Information which are substantially similar in scope and duration to those set forth in this Article 6; and 

(b) a Recipient may disclose Proprietary Information of the Disclosing Party to government or other regulatory authorities to
the extent that such disclosure is: (i) required by applicable law (including applicable securities law), government regulation or court order; or (ii) is reasonably necessary to Prosecute and Maintain any patent, to obtain any
authorization to conduct clinical studies, or to obtain any U.S. Food & Drug Administration (or equivalent) marketing approval/clearance for a Mapping Product or Sequencing Product; provided that, in case of any disclosures required by law,
the Recipient shall provide reasonable advance notice to the Disclosing Party to allow such Party to oppose such disclosure or to request confidential treatment of such Proprietary Information. 

6.3 Nondisclosure of Terms. Each Party agrees not to disclose the terms of this Agreement to any Third Party without
the prior written consent of the other Party, except: (a) to such Party’s advisors (including financial advisors, attorneys and accountants), potential and existing investors and others on a need-to-know basis, in each case under appropriate confidentiality obligations which are substantially similar in scope and duration to those set forth in this Article 6; or (b) to the extent necessary
to comply with applicable law (including applicable securities law), government regulation or court order; provided that the Party required to make such disclosure under (b) above shall promptly notify the other Party and (other than in the
case where such disclosure is necessary to comply with applicable securities laws) allow such other Party a reasonable opportunity to oppose such disclosure and/or to seek limitations on the portion of the Agreement required to be disclosed. 

ARTICLE VII 

INTELLECTUAL PROPERTY AND INFRINGEMENT 

7.1 Patent Maintenance. 

(a) Allocation of Responsibilities. As between the Parties, PacBio shall have the sole right, but not the obligation,
to control the prosecution and maintenance of the Sublicensed Patents in the Territory, using counsel selected by PacBio or its licensor. 

  
 -7- 

 (b) Maintenance Costs. BioNano will reimburse PacBio for all amounts due
after the Effective Date for patent annuities for maintenance of the Sublicensed Patents in the United States, provided that such amounts shall be prorated if PacBio grants any Third Party a sublicense to the Sublicensed Patents in the
Mapping Field or Sequencing Field. 
 7.2 Enforcement of Patents. 

(a) Notice. In the event BioNano learns of any Third Party infringement of the Sublicensed Patents by the manufacture,
use, sale, offer for sale or importation of a product in the Territory in the Mapping Field or the Sequencing Field, it shall promptly provide written notice to PacBio of such infringement and shall supply PacBio with all evidence it
possesses pertaining to such infringement (an “Infringement”). 
 (b) Infringement Action. As
between the Parties, PacBio or its nominee shall have the sole right, but not the obligation, to seek to abate any Infringement of any Sublicensed Patent. 

(c) Settlement and Recoveries. Any recovery obtained by PacBio as a result of an Infringement Action shall be retained
solely by PacBio. 
 ARTICLE VIII 

TERM AND TERMINATION 

8.1 Term. This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to Sections 8.2,
8.3 or 8.4, shall continue in full force and effect until expiration of the last-to-expire patent among the Sublicensed Patents. 

8.2 Termination for Material Breach. If either Party materially breaches this Agreement at any time, the non-breaching Party shall have the right to terminate this Agreement by written notice to the breaching Party, if such breach is not cured within thirty (30) days after written notice is given by the non-breaching Party to the breaching Party specifying the breach. 
 8.3 Termination by
BioNano. This Agreement may be terminated by BioNano, in its sole discretion, in its entirety, upon sixty (60) days’ prior written notice to PacBio. 

8.4 Termination by PacBio. If BioNano has not paid PacBio the first installment payment of one hundred six
thousand two hundred fifty dollars ($106,250) in accordance with Section 4.1 within three (3) months after the Effective Date, or if BioNano fails to pay the second, third or fourth installment payment by the respective due date set
forth in Section 4.1, then PacBio shall have the right to terminate this Agreement, with immediate effect, by written notice to BioNano. 

  
 -8- 

 8.5 Effect of Expiration or Termination. 

(a) Termination for Cause by PacBio or Termination by BioNano. Upon termination of this Agreement by PacBio or by
BioNano in accordance with Section 8.2, or termination of this Agreement by BioNano in accordance with Section 8.3, or termination of this Agreement by PacBio in accordance with Section 8.4: the option, licenses and rights granted by
PacBio to BioNano under Article 2 will immediately terminate; provided that BioNano shall remain responsible for, and shall pay, any and all payments due to PacBio under the terms of this Agreement as of the effective date of any such
termination. 
 (b) Survival of Certain Obligations. Subject to Section 8.5, expiration or termination of this
Agreement for any reason shall not relieve either Party of any obligation accruing on or prior to such expiration or termination, or which is attributable to a period prior to such expiration or termination, nor preclude either Party from
pursuing any rights and remedies it may have under this Agreement, or at law or in equity, which accrued or are based upon any event occurring prior to such expiration or termination. The provisions of Articles 1, 6, 8, 10,. and 11
shall survive the expiration or termination of this Agreement for any reason. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 

9.1 General Representations and Warranties. Each Party represents and warrants to the other Party that: 

(a) it is a corporation duly organized and validly existing under the laws of the jurisdiction in which it is incorporated;

 (b) it has full corporate power and authority, and has obtained all approvals, permits and consents necessary, to enter
into this Agreement and to perform its obligations hereunder; 
 (c) this Agreement is legally binding upon it and
enforceable in accordance with its terms; and 
 (d) the execution, delivery and performance of this Agreement does not
conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any governmental or regulatory authority having jurisdiction
over it. 
 9.2 Additional Warranties of PacBio. PacBio hereby covenants, represents and warrants to BioNano that:

 (a) as of the Effective Date, PacBio has a valid and enforceable written license from [...***...] to the Sublicensed
Patents; such license is in full force and effect; [...***...] has not provided PacBio with any notice of breach of such license (except with regard to any  

  
 ***Confidential
Treatment Requested 
  
 9 

 breach that has been cured prior to the Effective Date); PacBio is in compliance with all
material terms of such license; and [...***...] has no current right to terminate such license; 
 (b) PacBio will
maintain such license in effect until expiration or termination of this Agreement under Article VIII; and 
 (c) PacBio has
all rights necessary to grant to BioNano the sublicenses and rights granted under this Agreement. 
 9.3 DISCLAIMER.
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
NON1NFRINGEMENT, OR VALIDITY OF ANY PATENTS ISSUED OR PENDING. 
 ARTICLE X 

INDEMNIFICATION 

10.1 Indemnification by BioNano. BioNano will indemnify and hold harmless PacBio and its Affiliates and their
officers, directors, employees, agents, successors and assigns from and against any and all claims (including claims for death, illness, personal injury, property damage or improper business practices), liabilities, losses, damages, costs and
expenses, interest, awards, judgments and penalties (including, without limitation, reasonable attorneys’ fees and expenses) (“Losses”) suffered or incurred by them arising out of or resulting from: (a) the manufacture,
use, sale, or other disposition of Mapping Products or Sequencing Products by or on behalf of BioNano, any of its Affiliates, or their respective customers; (b) a Third Party’s use of Mapping Products or Sequencing Products purchased,
leased, or otherwise acquired from BioNano, any of its Affiliates, or their respective customers; (c) a Third Party’s manufacture or provision of Mapping Products or Sequencing Products at the request of BioNano or any of its Affiliates.

 10.2 Indemnification Procedures. In the event that PacBio intends to claim indemnification under this Article 10,
PacBio shall promptly notify BioNano in writing of the alleged Losses. BioNano shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably acceptable to PacBio; provided, however, that PacBio
shall have the right to retain its own counsel at its own expense, for any reason, including if representation of PacBio by the counsel retained by BioNano would be inappropriate due to actual or potential differing interests between such PacBio and
any other party represented by such counsel in such proceeding. PacBio shall cooperate with BioNano and its legal representatives in the investigation of any Losses covered by this Article 10. PacBio shall not, except at its own cost, voluntarily
make any payment or incur any expense with respect to any claim or suit without the prior written consent of BioNano, which BioNano shall not be required to give. 

  
 ***Confidential
Treatment Requested 
 -10- 

 10.3 Workers’ Compensation Insurance. BioNano shall at all times
comply, through insurance or self-insurance, with all statutory workers’ compensation and employers’ liability requirements covering any and all employees with respect to activities performed under this Agreement. 

10.4 Liability Insurance. BioNano agrees to obtain and maintain insurance against liability, damage, destruction and
loss comparable to that which is maintained by companies in similar businesses at similar stages in their growth. 

  
 -11- 

 ARTICLE XI 

MISCELLANEOUS 

11.1 Force Majeure. Neither Party shall be held liable or responsible to the other Party, nor be deemed to have
defaulted under or breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement, other than the payment of money owed by BioNano, to the extent, and for so long as, such failure or delay is caused by or
results from causes beyond the reasonable control of the affected Party, including fire, flood, embargo, power shortage or failure, war, act of war (whether war be declared or not), insurrection, riot, terrorism, civil commotion, strike, lockout or
other labor disturbance, act of God or any act, omission or delay in acting by any governmental authority or the other Party. 

11.2 Assignment. Except as provided in Section 11.3 of this Agreement, licenses granted to BioNano are personal,
and this Agreement and any licenses or rights granted to BioNano may not be assigned or otherwise transferred by BioNano without the consent of PacBio, which consent shall not be unreasonably withheld, and any purported assignment of this Agreement
by BioNano without PacBio’s consent shall be null and void. Any permitted assignee shall assume all obligations of its assignor under this Agreement. 

11.3 Acquisition of BioNano. In the event of an Acquisition of BioNano or of an Affiliate of BioNano, the sublicenses
granted herein may be assigned to or assumed by the acquiring party without the consent of PacBio. However, in the event that the Sequencing Field Option has already been exercised at the time of the Acquisition, [...***...]; otherwise, if and
when the Sequencing Field Option is exercised after the Acquisition, the [...***...]. Notwithstanding the foregoing, if BioNano’s Affiliate is Acquired and such Affiliate is no longer an Affiliate of BioNano after such transaction, the
sublicenses granted herein to such Affiliate will terminate. 
 11.4 Severability. If one or more provisions of this
Agreement is held to be invalid, illegal or unenforceable, the Parties shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions are, in their economic effect, sufficiently
similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such provisions. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability
of one or more provisions of the Agreement shall not affect the validity of this Agreement as a whole, unless the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not
have entered into this Agreement without such invalid provisions. 
 11.5 Notices. Any notice, consent or report
required or permitted to be given or made under this Agreement by one Party to the other Party shall be in English and in writing, delivered personally or by facsimile (receipt verified and a copy promptly sent by personal delivery, U.S. 

  
 ***Confidential
Treatment Requested 
 -12- 

 first class mail or express courier providing evidence of receipt, postage prepaid (where
applicable)), or by U.S. first class mail or express courier providing evidence of receipt, postage prepaid (where applicable), at the following address for a Party (or such other address for a Party as may be specified by like notice): 

To PacBio: 

Pacific Biosciences of California, Inc. 

1380 Willow Rd. 

Menlo Park, CA 94025 

Attention: Legal Department 

Facsimile: (650) 323-9420 

To BioNano: 

BioNano Genomics, Inc. 

9640 Towne Centre Drive, Ste. 100 

San Diego, CA 92121 

Attention: Chief Executive Officer 

Facsimile: (858) 888-7601 

All such notices, consents or reports shall be effective upon receipt. 

11.6 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of State of
California, without regard to the conflicts of law principles thereof. Any claim or dispute arising out of or related to this Agreement shall be subject to the sole jurisdiction and venue of the state and federal courts located in Santa Clara
County. 
 11.7 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY PUNITIVE, SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY; PROVIDED HOWEVER THAT NOTHING IN THIS SECTION 11.7 SHALL BE DEEMED TO LIMIT THE INDEMNIFICATION OBLIGATIONS OF EITHER PARTY
UNDER ARTICLE 10 TO THE EXTENT A THIRD PARTY RECOVERS ANY PUNITIVE, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES FROM AN INDEMNITEE. 

11.8 Entire Agreement. This Agreement (including the Exhibits attached hereto) contains the entire agreement by the
Parties with respect to the subject matter hereof and supersede any prior and contemporaneous express or implied agreements, understandings and 

  
 -13- 

 representations, either oral or written, which may have related to the subject matter hereof in
any way. 
 11.9 Interpretation. The captions to the several Articles and Sections of this Agreement are not a part
of this Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without
limitation” or like expression; (b) the singular shall include the plural and vice versa; and (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable. The Parties acknowledge and agree that they
have selected the up-front, option and royalty payment structure for the Mapping Field and Sequencing Field, as described in this Agreement, as the most appropriate and convenient approach to determine the value of the sublicense to BioNano under
the Sublicensed Patents, as described in this Agreement. 
 11.10 Independent Contractors. It is expressly agreed
that PacBio and BioNano shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency or fiduciary relationship. Neither PacBio nor BioNano shall have the authority to
make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party to do so. 

11.11 Waiver; Amendment. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be
waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any time to require performance of any provision of this Agreement shall in no manner affect such
Party’s rights at a later time to enforce the same. This Agreement may be amended, and any term of this Agreement may be modified, only by a written instrument executed by a duly authorized representative of each Party. 

11.12 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. 
 11.13 Binding Effect. This
Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns. 

[Remainder of page intentionally left blank.] 

  
 -14- 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth
above. 
  

			
	PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

			
		
	 BY:
	 	 /s/ Stephen M.
Moore

			
	 NAME:
	 	 Stephen M. Moore

	 TITLE:
	 	 Vice President & General Counsel

  

			
	 BIONANO GENOMICS, INC.

		
	 BY:
	 	 /s/ R. Erik
Holmlin

			
	 NAME:
	 	 R. Erik Holmlin

	 TITLE:
	 	 President & CEO

 EXHIBIT 1.7 

Sublicensed Patents 
  

					
	 Family
	  	 Patent No.
	  	 Title

			
	1	  	[ *** ]	  	[ *** ]
			
	2	  	[ *** ]	  	[ *** ]
			
	 	  	[ *** ]	  	[ *** ]
	  	[ *** ]	  	[ *** ]
			
	3	  	[ *** ]	  	[ *** ]
			
	4	  	[ *** ]	  	[ *** ]
			
	 	  	[ *** ]	  	[ *** ]
			
	5	  	[ *** ]	  	[ *** ]
			
	 	  	[ *** ]	  	] *** ]

  
 ***Confidential
Treatment Requested 

 EXHIBIT 2.4 

Financial Provisions for Sequencing Products 

A. “Net Sales” shall mean [...***...]. 

Each of the foregoing [...***...]. 

Net Sales also includes the [...***...]. 

B. Royalty Payments. 

(a) Royalty Rate. Subject to the terms and conditions of this Agreement, if BioNano exercises the Sequencing Field
Option, BioNano shall pay to PacBio a royalty of [...***...]. 
 (b) Currency Conversion. If any currency
conversion shall be required in connection with the payment of any royalties under this Agreement, such conversion shall be made by using the average of the exchange rates for the purchase and sale of United States Dollars [...***...]. 

  
 ***Confidential
Treatment Requested 

 (c) One Royalty. No more than one royalty payment shall be due with
respect to a sale of a particular unit of Sequencing Product. 
 (d) Royalty Payment Terms. Royalties with respect to
Net Sales for a given [...***...] shall be due and payable on [...***...]. Late payments shall be subject to a per annum interest charge equal [...***...]. 

C. Reporting. 

(a) Commencing on the first commercial sale of a Sequencing Product in any country in the Territory, BioNano shall furnish to
PacBio a written report for each calendar quarter during the term of this Agreement showing: 
 (i) [...***...] of all
Sequencing Products sold by BioNano and its Affiliates in the Territory during such calendar quarter and [...***...]; 

(ii) the royalties, payable in United States Dollars, which shall have accrued under this Agreement based upon such Net Sales
of the Sequencing Products; 
 (iii) [...***...] not previously reported; and 

(iv) the exchange rates used in determining the amount of royalties payable in United States Dollars, as more specifically
provided in Section B(b) above. 
 (b) Reports to be provided by BioNano to PacBio shall be due [...***...] following
the close of each calendar quarter. 
 D. No Royalty Avoidance. BioNano agrees that it will not intentionally
structure its Net Sales or the consideration or compensation that it receives or is entitled to receive in such a way as to avoid any payment that would otherwise be due to PacBio under this Agreement. 

E. Records. BioNano shall keep and maintain, and shall require that its Affiliates keep and maintain, any and all
records necessary to certify compliance of BioNano and its Affiliates with this Agreement, including but not limited to accounting general ledgers, distributor agreements, price lists, catalogs, marketing materials, audited financial statements,
income tax returns, sales tax returns, inventory records, and shipping documents of Licensed Products. [...***...], which shall not unreasonably withhold such acceptance. As between the Parties, [...***...]. However, if the results of
any [...***...] reveal additional royalties owed to PacBio that differ by more the [...***...] from those royalties already paid, BioNano shall [...***...]. PacBio agrees to hold such records confidential, [...***...]. The
records required by this paragraph shall be maintained and available for inspection for a period of [...***...] following the calendar quarter to which they pertain. This paragraph shall survive termination of this Agreement. 

  
 ***Confidential
Treatment Requested 

 EXHIBIT 3.2 

[...***...] Licenses 
 Mapping
Field 
 [...***...] 
 Sequencing
Field 
 [...***...] 

  
 ***Confidential
Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]